# A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

> **NCT04033926** · PHASE2 · COMPLETED · sponsor: **Kezar Life Sciences, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Polymyositis
- Dermatomyositis

## Interventions

- **DRUG:** KZR-616
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04033926
- **Lead sponsor:** Kezar Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-14
- **Primary completion:** 2022-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033926, "A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04033926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*